CL2017003309A1 - Métodos de purificación y/o inactivación viral - Google Patents

Métodos de purificación y/o inactivación viral

Info

Publication number
CL2017003309A1
CL2017003309A1 CL2017003309A CL2017003309A CL2017003309A1 CL 2017003309 A1 CL2017003309 A1 CL 2017003309A1 CL 2017003309 A CL2017003309 A CL 2017003309A CL 2017003309 A CL2017003309 A CL 2017003309A CL 2017003309 A1 CL2017003309 A1 CL 2017003309A1
Authority
CL
Chile
Prior art keywords
purification
methods
viral inactivation
glicoprotein
inactivation
Prior art date
Application number
CL2017003309A
Other languages
English (en)
Inventor
Jenny Aharonov
Elinor Erez
Eli Harosh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2017003309A1 publication Critical patent/CL2017003309A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • B01D39/2003—Glass or glassy material
    • B01D39/2017—Glass or glassy material the material being filamentary or fibrous
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Geology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>MÉTODOS DE PURIFICACIÓN Y/O INACTIVACIÓN VIRAL (POR EJEMPLO, GLICOPROTEÍNA) QUE COMPRENDEN LA ETAPA DE TRATAR LA PROTEÍNA (POR EJEMPLO, GLICOPROTEÍNA) CON UNA COMBINACIÓN DE ÁCIDO CAPRÍLICO Y ETANOL.</p>
CL2017003309A 2015-06-26 2017-12-21 Métodos de purificación y/o inactivación viral CL2017003309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15174029 2015-06-26

Publications (1)

Publication Number Publication Date
CL2017003309A1 true CL2017003309A1 (es) 2018-04-20

Family

ID=53510646

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003309A CL2017003309A1 (es) 2015-06-26 2017-12-21 Métodos de purificación y/o inactivación viral

Country Status (15)

Country Link
US (1) US10906953B2 (es)
EP (2) EP3628675A1 (es)
JP (2) JP6845813B2 (es)
KR (1) KR102714934B1 (es)
CN (2) CN115028675A (es)
AU (1) AU2016282916B2 (es)
CA (1) CA2990311A1 (es)
CL (1) CL2017003309A1 (es)
CO (1) CO2018000171A2 (es)
ES (1) ES2770860T3 (es)
MX (1) MX381279B (es)
MY (1) MY179524A (es)
PH (1) PH12017502386A1 (es)
RU (1) RU2719468C2 (es)
WO (1) WO2016207353A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50034B1 (fr) 2017-09-01 2022-02-28 Ferring Bv Composition de stimulation ovarienne contrôlée
CN110563832B (zh) * 2019-07-31 2025-11-14 江苏璟泽生物医药有限公司 一种高纯度重组促卵泡刺激素纯化方法
CN110305903B (zh) * 2019-07-31 2021-10-01 江苏璟泽生物医药有限公司 重组人促卵泡激素及其制备方法
KR200493431Y1 (ko) 2019-10-23 2021-03-29 (주)에르젠아웃도어 다기능 캠핑용 타프
KR20220020526A (ko) 2020-08-12 2022-02-21 주식회사 엘지화학 유체 흐름 분배기가 구비된 열교환기
CN116457081A (zh) * 2020-10-19 2023-07-18 赛多利斯层析设备 用于纯化生物分子的设备和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1311764A (fr) 1959-12-29 1962-12-14 Procédé de purification de la gonadotropine folliculo-stimulante
FR2580503B1 (fr) 1985-04-23 1988-02-19 Limousin Inst Bio Perfectionnements apportes a la preparation des inhibiteurs de l'adhesion cellulaire, anti-adhesines ainsi obtenues et medicaments et aliments les contenant
US4939176A (en) * 1988-12-20 1990-07-03 Miles Inc. Viral inactivation process
ES2224094T3 (es) * 1990-04-19 2005-03-01 Bayer Corporation Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica.
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
AU3624400A (en) 1999-03-19 2000-10-09 Bayer Corporation Chromatographic albumin process
WO2005014648A1 (en) * 2003-08-12 2005-02-17 Octapharma Ag Process for preparing an alpha-1-antitrypsin solution
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
CN101397339B (zh) 2008-09-24 2012-07-25 上海天伟生物制药有限公司 糖蛋白中去除/灭活病毒的方法
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
CN103476786B (zh) * 2011-04-08 2018-06-05 哥斯达黎加大学 一种生产血液来源蛋白质注射制剂的方法，以及使用上述方法获得的蛋白质物料
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CN103275206B (zh) * 2013-03-17 2014-09-10 赤峰博恩药业有限公司 孕马血清促性腺激素的提纯方法
KR102356757B1 (ko) 2013-10-18 2022-02-03 노바셉 이큅먼트 솔루션즈 단백질 정제

Also Published As

Publication number Publication date
US10906953B2 (en) 2021-02-02
CN115028675A (zh) 2022-09-09
CO2018000171A2 (es) 2018-04-30
AU2016282916B2 (en) 2022-01-20
KR102714934B1 (ko) 2024-10-07
HK1253557A1 (en) 2019-06-21
WO2016207353A1 (en) 2016-12-29
ES2770860T3 (es) 2020-07-03
RU2719468C2 (ru) 2020-04-17
EP3628675A1 (en) 2020-04-01
JP6845813B2 (ja) 2021-03-24
MX2017016437A (es) 2018-03-02
AU2016282916A1 (en) 2017-12-21
US20190002518A1 (en) 2019-01-03
RU2017145983A3 (es) 2019-09-05
EP3313859B1 (en) 2019-11-20
PH12017502386B1 (en) 2018-06-25
CA2990311A1 (en) 2016-12-29
EP3313859A1 (en) 2018-05-02
CN107709350A (zh) 2018-02-16
MX381279B (es) 2025-03-12
JP2018521049A (ja) 2018-08-02
RU2017145983A (ru) 2019-07-29
JP2021036876A (ja) 2021-03-11
MY179524A (en) 2020-11-10
KR20180020982A (ko) 2018-02-28
PH12017502386A1 (en) 2018-06-25
JP7061654B2 (ja) 2022-04-28

Similar Documents

Publication Publication Date Title
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2025009360A (es) Medios y metodo para preparar vectores virales y usos de los mismos
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX383652B (es) Moduladores de la vía de estrés integrada.
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
MX386418B (es) Composicion acida que comprende una ficocianina.
EA201992546A1 (ru) Средства на основе антител к cd33
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
CL2019002605A1 (es) Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas.
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS